CNMP EGFR mutado. A favor de no hacer secuenciación

18 / 38

FLAURA: Time to Treatment Discontinuation (TDT) and
Time to First Subsequent Therapy (TFST)
CNS progression events occurred in 17 (6%) vs 42 (15%) patients receiving osimertinib vs SoC (all patients)